Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples

被引：9
作者：
Combe, Bernard [1 ]
van Vollenhoven, Ronald [2 ]
机构：
[1] Univ Montpellier I, Lapeyronie Hosp, Dept Rheumatol, Montpellier, France
[2] Karolinska Inst, Dept Med, Unit Clin Therapy Res Inflammatory Dis ClinTRID, Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 09期
关键词：
Rheumatoid Arthritis; DMARDs (biologic); Treatment; INADEQUATE RESPONSE; DOUBLE-BLIND; EULAR RECOMMENDATIONS; MONOCLONAL-ANTIBODY; NECROSIS-FACTOR; GM-CSF; PLACEBO; METHOTREXATE; MAVRILIMUMAB; ETANERCEPT;
D O I：
10.1136/annrheumdis-2013-203261
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1433 / 1435
页数：3
相关论文
共 25 条
[1]   Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis [J].
Burmester, Gerd R. ;
Weinblatt, Michael E. ;
McInnes, Iain B. ;
Porter, Duncan ;
Barbarash, Olga ;
Vatutin, Mykola ;
Szombati, Istvan ;
Esfandiari, Ehsanollah ;
Sleeman, Matthew A. ;
Kane, Christopher D. ;
Cavet, Guy ;
Wang, Bing ;
Godwood, Alex ;
Magrini, Fabio .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) :1445-1452
[2]   Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study [J].
Burmester, Gerd R. ;
Feist, Eugen ;
Sleeman, Matthew A. ;
Wang, Bing ;
White, Barbara ;
Magrini, Fabio .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (09) :1542-1549
[3]   G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis [J].
Cornish, Ann L. ;
Campbell, Ian K. ;
McKenzie, Brent S. ;
Chatfield, Simon ;
Wicks, Ian P. .
NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (10) :554-559
[4]   Targeting BAFF in autoimmunity [J].
Davidson, Anne .
CURRENT OPINION IN IMMUNOLOGY, 2010, 22 (06) :732-739
[5]   Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response [J].
Emery, P. ;
Doerner, T. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (12) :2063-2070
[6]   Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs [J].
Fleischmann, Roy ;
Cutolo, Maurizio ;
Genovese, Mark C. ;
Lee, Eun Bong ;
Kanik, Keith S. ;
Sadis, Seth ;
Connell, Carol A. ;
Gruben, David ;
Krishnaswami, Sriram ;
Wallenstein, Gene ;
Wilkinson, Bethanie E. ;
Zwillich, Samuel H. .
ARTHRITIS AND RHEUMATISM, 2012, 64 (03) :617-629
[7]   A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate [J].
Genovese, Mark C. ;
Lee, Eric ;
Satterwhite, Julie ;
Veenhuizen, Melissa ;
Disch, Damon ;
Berclaz, Pierre-Yves ;
Myers, Stephen ;
Sides, Gregory ;
Benichou, Olivier .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) :1453-1460
[8]   Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors [J].
Genovese, Mark C. ;
Fleischmann, Roy M. ;
Greenwald, Maria ;
Satterwhite, Julie ;
Veenhuizen, Melissa ;
Xie, Li ;
Berclaz, Pierre-Yves ;
Myers, Stephen ;
Benichou, Olivier .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) :1461-1468
[9]   Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate [J].
Genovese, MC ;
Cohen, S ;
Moreland, L ;
Lium, D ;
Robbins, S ;
Newmark, R ;
Bekker, P .
ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1412-1419
[10]  
Genovese MC, 2005, ARTHRITIS RHEUM, V52, pS1989
123